I think Vancocin will keep climbing in prescriptions. I think the kicker for Vphm will be the announcements coming this winter. The trials progress will add some pizzazz to the stock by adding the potential of the pipeline. Most biotechs are not profitable and trade up and down strictly on their potential. The trials results will add that factor to the share price of Vancocin. Action by Schering to advance Pleconaril towards trials will add another element of anticipation.
I also think it's highly likely that Vphm will announce a purchase of another niche drug in the next 6 months. Given their success with Vancocin, markets would welcome another source of revs.
Stock should do fine. I am going to raise some cash this week and try to buy some more options to get more leverage in Vphm in the short term. LEAPS look pretty expensive but I will check them out when I have the cash. Bobwins
Me too, I have a huge position in VPHM and I am still holding on to it. I am planning to take some profits when it hits 25 at the year end rally. Am I too optimistic?
News 
Market Data 
Discover 
AI
